(Q80408154)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17539192%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

review article

1 reference

title

Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17539192%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

0 references

1 reference

1 reference

1 March 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17539192%20AND%20SRC:MED&resulttype=core&format=json

Clinical Colorectal Cancer

31 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17539192%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17539192%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17539192%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

407-422

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17539192%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Systemic therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Capecitabine as adjuvant treatment for stage III colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art.

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosa

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Relationship between fluorouracil systemic exposure and tumor response and patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

DoseVersus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Population Pharmacokinetics/Dynamics*

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Population study of dihydropyrimidine dehydrogenase in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Nomenclature for human DPYD alleles

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinom

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Known variant DPYD alleles do not explain DPD deficiency in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Pharmacogenetics of capecitabine in advanced breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Thymidylate synthase pharmacogenetics

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Neurotoxic effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on dogs

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Simple and sensitive determination of 5-fluorouracil in plasma by high-performance liquid chromatography. Application to clinical pharmacokinetic studies

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Synthesis of new d-propoxyphene derivatives and the development of a microparticle-based immunoassay for the detection of propoxyphene and norpropoxyphene

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

New synthesis and characterization of (+)-lysergic acid diethylamide (LSD) derivatives and the development of a microparticle-based immunoassay for the detection of LSD and its metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

Evaluation of the online immunoassay for propoxyphene: comparison to EMIT II and GC-MS

1 reference

https://api.crossref.org/works/10.1016%2FS1533-0028%2811%2970480-7

7 January 2021

10.1016/S1533-0028(11)70480-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17539192%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference